Tumor News and Research

RSS

Joslin study uncovers potential targets for soft-tissue sarcomas

Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

30 Nov 2011

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Nov 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Blood stem cells engineered to create cancer-killing T-cells

Researchers from UCLA's cancer and stem cell centers have demonstrated for the first time that blood stem cells can be engineered to create cancer-killing T-cells that seek out and attack a human melanoma. The researchers believe this approach could be useful in 40 percent of Caucasians with this malignancy.

29 Nov 2011

Second biopsy for suspected recurrent breast cancer can alter treatment

A second, larger clinical research study led by breast cancer specialists at Princess Margaret Hospital (PMH) has again proven that comparing a new biopsy of progressing or recurring cancer with that of the original cancer can dictate a change in treatment.

29 Nov 2011

Seizure drug slows spread of uveal melanoma

A drug commonly used to treat seizures appears to make eye tumors less likely to grow if they spread to other parts of the body, according to researchers at Washington University School of Medicine in St. Louis.

29 Nov 2011

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults.

29 Nov 2011

Scientists identify cellular protein that plays central role in formation of new blood vessels

Scientists at the University of North Carolina at Chapel Hill School of Medicine have identified a cellular protein that plays a central role in the formation of new blood vessels.

29 Nov 2011

Bone cell factor can lull prostate tumor cells to sleep

Prostate tumor cells can be lulled to sleep by a factor released by bone cells, according to a study published online this week in the Journal of Experimental Medicine. Disease recurs in up to half of prostate cancer patients after treatment, often as a result of metastases that spread to distant organs.

29 Nov 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011

New protein involved in defense mechanism against cancer

Researchers of the Swedish medical university Karolinska Institutet and the University of Cologne, Germany, have identified a new protein involved in a defense mechanism against cancer.

28 Nov 2011

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

25 Nov 2011

Transplantation of tissue-engineered windpipe can benefit patients with tracheal cancer

Tracheal tumors can be surgically removed, but most are too large for the surgery to be successful by the time they are discovered. Therefore, new therapeutic options are needed. Even in patients with operable tumors, the proportion of complete tumor resection is less than 60%. This outcome would be greatly improved if a trachea substitute with similar anatomical, physiological and biomechanical properties of the patient's original trachea were available.

24 Nov 2011

Combination of radiation treatment and LY2109761 can prevent glioblastoma

Glioblastoma is regarded as the most malignant form of brain tumor. In many cases, neurosurgeons are not able to remove such tumors completely because of the risk of destroying too much brain tissue in the process. Moreover, it is often impossible to identify all the fine extensions by which the tumor spreads into surrounding healthy tissue. To at least slow down the growth of tumor cells that have remained in the head, almost all glioblastoma patients are treated by radiotherapy after surgery.

24 Nov 2011